Acta Pharmaceutica Sinica B

Supplementary data

Short Communication

Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1

Xuewei Cheng[a,c,†], Xia Lv[b,†], Hengyan Qu[a], Dandan Li[a], Mengmeng Hu[a], Wenzhi Guo[d], Guangbo Ge[c,*], Ruihua Dong[a,]**

[a]*Clinical Pharmacology Laboratory, Military Academy of Medical Science Hospital, Beijing 100071, China*

[b]*College of Life Science, Dalian Nationalities University, Dalian 116600, China*

[c]*Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China*

[d]*Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, China*

Received 5 April 2017; received in revised form 15 June 2017; accepted 30 June 2017

[*]Corresponding author. Tel.: +86 411 843793171.

[**]Corresponding author. Tel.: +86 10 66947482.

E-mail address: geguangbo@dicp.ac.cn (Guangbo Ge), sm.8056@163.com (Ruihua Dong).

[†]These authors made equal contributions to this work.



Figure S1 Inhibitory effects of icotinib and erlotinib on the catalytic activities of NCHN-*O*-glucuronidation in human recombinant UGT1A1 (A) and HLMs (B). Each column represents the mean of triplicate determinations.



Figure S2 The Dixon plots for inhibition of icotinib and erlotinib against UGT1A1-mediated NCHN-*O*-glucuronidation in recombinant UGT1A1 (A and B) and HLMs (C and D).